|Bid||41.57 x 900|
|Ask||41.86 x 800|
|Day's Range||41.27 - 42.94|
|52 Week Range||16.09 - 75.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The biotech sector was in focus last week with guidance updates from quite a few biotechs like Gilead (GILD). Additionally, updates on coronavirus treatments from Regeneron (REGN) and Vir (VIR) were in focus.
Vir Biotechnology (VIR) and its British partner, Glaxo announces agreement umder which they will evaluate their second coronavirus therapeutic candidate.
Shares of Vir Biotechnology (NASDAQ: VIR) were vaulting 12.8% higher as of 3:07 p.m. EST on Tuesday. The big jump came after the company announced news about separate collaborations with Gilead Sciences (NASDAQ: GILD) and GlaxoSmithKline (NYSE: GSK). Vir and Gilead plan to work together on a phase 2 study evaluating Vir's VIR-2218 with Gilead's selgantolimod in treating individuals infected with the hepatitis B virus (HBV).